How Should Ovarian Cancer Survivors Be Monitored for Relapse?

Treating an ovarian cancer relapse as soon as it can be detected seems like a good idea. But not so fast, a major study has concluded.  

KAREN PATTERSON
PUBLISHED: 1:00 AM, MON SEPTEMBER 14, 2009
Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
Treating an ovarian cancer relapse as soon as it can be detected seems like a good idea. But not so fast, a major study has concluded.

The study involved women with advanced ovarian cancer in complete remission after surgery and platinum-based chemotherapy. The goal was to determine whether these women benefit from new chemotherapy initiated after levels of the blood marker CA-125 increase to a particular threshold—but before physical symptoms appear.

The research found no difference in overall survival for women whose relapse was treated earlier, compared with women whose chemotherapy was delayed until symptoms arose. Also, the women whose treatment began later scored better on quality of life measures.

The findings didn’t surprise Gordon Rustin, MD, director of medical oncology at Mount Vernon Cancer Centre in Middlesex, United Kingdom, who, on behalf of U.K. and other European collaborators, presented the study’s results last spring at a meeting of the American Society of Clinical Oncology. “I tell my patients that if they feel well and have no symptoms suggesting relapse, they are better off not having CA-125 measured during follow-up,” he says. “The major change in my advice is that if I now have a patient who has a rising CA-125 but is very well, I tell them that they can safely delay chemotherapy until they develop symptoms.”

Participants in the study, which enrolled more than 1,440 patients in 10 countries, underwent quarterly tests for CA-125. Among the 37 percent (529 patients) whose CA-125 levels reached twice the upper limit of normal before symptoms appeared, half were randomized to be informed of the increase and started treatment within four weeks; half were not informed, but continued getting CA-125 tests and began treatment after symptoms appeared. Eighty percent of patients with advanced ovarian cancer relapse after first-line chemotherapy, and most benefit from further therapy, says Rustin.

In the U.S., CA-125 holds a primary place in gauging ovarian cancer activity, says Beth Karlan, MD, director of the Women’s Cancer Research Institute and gynecologic oncology at Cedars-Sinai Medical Center in Los Angeles. While no firm guidelines are in place, quarterly monitoring of CA-125 levels, along with imaging (such as CT or PET/CT) once or twice a year, is common in monitoring women with advanced ovarian epithelial cancer in remission. 

Karlan notes the study’s findings don’t apply to everybody—for instance, the fraction of patients who have access via clinical trials to new treatments that might work differently than standard chemotherapy regimens. The study also didn’t address variations in the second- or third-line therapies administered, differences in how responsive a patient’s cancer was to chemotherapy with a platinum-containing drug, or the potential impact of secondary surgical debulking (to remove as much of the cancer as possible) in treating some recurrences.

At about $50, CA-125 testing is relatively inexpensive, but it extracts another toll—women’s extreme anxiety about each result, Karlan says. Also, she says, for the women who restart chemotherapy based on rising but relatively low levels of CA-125 alone, quality of life suffers, most likely due to more time spent in treatment and cumulative toxicities such as neuropathy.

Talk about this article with other patients, caregivers, and advocates in the Ovarian CURE discussion group.
Special Feature
Share Your Art
Related Articles
Oral Contraceptive Use Leads to Better Outcomes in Patients With Ovarian Cancer
Those who had taken birth control pills prior to their cancer diagnosis had improved progression-free survival compared with those who had not taken contraceptives.
Making the Case for Neoadjuvant Chemotherapy in Ovarian Cancer
Neoadjuvant chemotherapy is increasingly used in advanced ovarian cancer, even though it has not been shown to improve survival versus primary cytoreduction.
Expert Cautious About Immunotherapy for Ovarian Cancer
"It's not because there's evidence that they don't work — it's just that there's no evidence at all," Maurie Markman says.
Related Videos
Jessica Safran Provides Advice on Picking a Wig After Chemotherapy
Safran is the Executive Director of The Identity Shift Project, which aims to bring new perspectives to healing through collaborative art making.
Melinda Liggett Irwin on Exercise and Fatigue in Women Diagnosed With Ovarian Cancer
Melinda Liggett Irwin, discusses The Women's Activity and Lifestyle Study in Connecticut (WALC) study, a randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer.
Adele Croteau Discusses the Impact of Her Mother's Cancer
We sat down with Adele Croteau, a survivor of cervical cancer from Ottawa, Canada, at I Had Cancer's "A Celebration of Shared Experiences Honoring You."
$auto_registration$